The Hutchinson Center is a world-leader in research to improve HIV prevention and treatment:
Home of the world’s largest HIV vaccine trials network — Hutchinson Center researchers lead the HIV Vaccine Trials Network (HVTN), an international collaboration dedicated to stopping HIV's spread in the U.S. and around the world. Based in Seattle, the network is the largest clinical trials program devoted to HIV vaccines. The network’s HIV vaccine trial units are located at leading research institutions in 27 cities on four continents.
Making HIV vulnerable to immunotherapy — Research by Drs. Julie Overbaugh and colleagues could provide important clues for designing an HIV vaccine. The researchers found that two simple mutations in a certain HIV-1 strain could render it vulnerable to attack by the body's immune system. These findings could form the foundation for vaccines that help the body to fight off HIV.
Using statistics to unravel global HIV — The Hutchinson Center is home to the Statistical Center for HIV/AIDS Research and Prevention (SCHARP). SCHARP provides statistical help to researchers worldwide and also conducts a statistical methodology and mathematical modeling research program. SCHARP also collects, manages and analyzes data from clinical trials and studies dedicated to eliminating HIV/AIDS.
Understanding HIV vulnerability's ancient origins — Why are humans vulnerable to HIV today? The answer may lie in evidence of human immunity to a virus that infected chimpanzees 4 million years ago, according to research by Drs. Michael Emerman and Harmit Malik. Learn more »
Curbing HIV spread in women — Research led by Drs. Florian Hladik and Julie McElrath could lead to new strategies to prevent HIV-1 transmission in women, who typically contract HIV through sexual contact. The researchers identified two different types of immune cells in the vagina that HIV-1 simultaneously enters. Their findings could inform prevention measures that interfere with vaginal HIV infection. Learn more »
Developing new approaches to vaccination — Dr. Ann Duerr leads innovative research and clinical trials that advance the search for an effective HIV vaccine. Duerr is examining whether vaccines can be more effective if they are administered through mucosal surfaces, such as the nose and mouth, instead of the blood stream.
Investigating why some HIV patients stay symptom free — Drs. Julie McElrath, Jennifer Lund and colleagues are investigating why “long-term non-progressors” – the five to ten percent of patients with HIV who go more than a decade without progressing to AIDS or developing other symptoms – can control the virus. This research’s goal is to gain insights that could someday improve outcomes among a much broader group of patients with HIV. Learn more »